Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder

被引:98
作者
Mattiasson, A [1 ]
Blaakaer, J
Hoye, K
Wein, AJ
机构
[1] Univ Lund Hosp, Dept Urol, S-22185 Lund, Sweden
[2] Skejby Hosp, Dept Obstet & Gynaecol, Aarhus, Denmark
[3] Helsetorget Legesenter, Elverum, Norway
[4] Univ Penn, Med Ctr, Div Urol, Philadelphia, PA 19104 USA
关键词
overactive bladder; tolterodine; bladder training;
D O I
10.1046/j.1464-410X.2003.03076.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
OBJECTIVES To compare the efficacy of tolterodine plus simplified bladder training (BT) with tolterodine alone in patients with an overactive bladder. PATIENTS AND METHODS In a multicentre, single-blind study at 51 Scandinavian centres, 505 patients aged greater than or equal to 18 years with symptoms of urinary frequency (greater than or equal to 8 micturitions/24 h) and urgency, with or without urge incontinence, were randomized to oral treatment with either tolterodine 2 mg twice daily plus simplified BT or tolterodine alone. Changes in voiding diary variables were evaluated after 2, 12 and 24 weeks of treatment. The patients' perceptions of their bladder symptoms and tolerability (adverse events) were also determined. RESULTS In all, 501 patients (75% women) were evaluable on an intention-to-treat basis (244 on tolterodine + BT and 257 on tolterodine alone). Tolterodine significantly reduced the voiding frequency and increased the volume voided per void at all sample times; these effects were significantly increased by adding BT. At the end of the study the median percentage reduction in voiding frequency was greater with tolterodine + BT than with tolterodine alone (33% vs 25%, P < 0.001), while the median percentage increase in volume voided per void was 31% with tolterodine + BT and 20% with tolterodine alone (P < 0.001). There was a median of 81% fewer incontinence episodes than at baseline with tolterodine alone, which was not significantly different from that with tolterodine + BT (- 87%). The two groups had comparable median percentage reductions in urgency episodes. Some 76% of patients on tolterodine + BT reported an improvement in their bladder symptoms relative to baseline, compared with 71% on tolterodine alone. Tolterodine was well tolerated; the most common adverse event was mild dry mouth. CONCLUSION Tolterodine 2 mg twice daily is an effective and well tolerated treatment for an overactive bladder, the effectiveness of which can be augmented by a simplified BT regimen.
引用
收藏
页码:54 / 60
页数:7
相关论文
共 16 条
[1]
Abrams P, 1998, BRIT J UROL, V81, P801
[2]
Twelve-month treatment of overactive bladder - Efficacy and tolerability of tolterodine [J].
Abrams, P ;
Malone-Lee, J ;
Jacquetin, B ;
Wyndaele, JJ ;
Tammela, T ;
Jonas, U ;
Wein, A .
DRUGS & AGING, 2001, 18 (07) :551-560
[3]
[Anonymous], 1996, AHCPR PUBLICATION
[4]
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis [J].
Appell, RA .
UROLOGY, 1997, 50 (6A) :90-96
[5]
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine [J].
Appell, RA ;
Abrams, P ;
Drutz, HP ;
Van Kerrebroeck, PEVA ;
Millard, R ;
Wein, A .
WORLD JOURNAL OF UROLOGY, 2001, 19 (02) :141-147
[6]
Combined behavioral and drug therapy for urge incontinence in older women [J].
Burgio, KL ;
Locher, JL ;
Goode, PS .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (04) :370-374
[7]
Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms [J].
Chancellor, M ;
Freedman, S ;
Mitcheson, HD ;
Antoci, J ;
Primus, G ;
Wein, A .
CLINICAL DRUG INVESTIGATION, 2000, 19 (02) :83-91
[8]
Tolterodine - A review of its use in the treatment of overactive bladder [J].
Clemett, D ;
Jarvis, B .
DRUGS & AGING, 2001, 18 (04) :277-304
[9]
Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder [J].
Drutz H.P. ;
Appell R.A. ;
Gleason D. ;
Klimberg I. ;
Radomski S. .
International Urogynecology Journal, 1999, 10 (5) :283-289
[10]
FERRIE BG, 1984, BRIT J UROL, V56, P482